Stock Market Concentration – S&P 500, STOXX Europe 600 and Topix
Stock Market Concentration – S&P 500, STOXX Europe 600 and Topix The S&P 500 remains highly concentrated in a few stocks. Image: Goldman Sachs Global Investment Research
Stock Market Concentration – S&P 500, STOXX Europe 600 and Topix The S&P 500 remains highly concentrated in a few stocks. Image: Goldman Sachs Global Investment Research
Valuation – Forward Price/Earnings Ratio – STOXX Europe 600 Index and S&P 500 Index U.S. equities look pricey relative to Europe. Image: Morgan Stanley Wealth Management
Performance – Nasdaq 100, Russell 2000, Stoxx Europe 600 Banks, MSCI All Countries Energy Welcome to the ‘everything rally’, despite the damage of the coronavirus pandemic on the global economy. Image: Financial Times
Valuation – MSCI ACWI and STOXX Europe 600 – 24-Month Forward P/E Percentile vs. History Should investors pay attention to stock valuation? Image: Goldman Sachs Global Investment Research
Earnings Sentiment (S&P 500 Index and STOXX Europe 600 Index) Earnings sentiment seems to have peak in the United States. Image: Goldman Sachs Global Investment Research
Euro/U.S. Dollar vs. Stoxx Europe 600 Index/S&P 500 Index Does the strength of the euro make European stocks a buying opportunity? Image: Morgan Stanley Wealth Management
Equity Index Price Returns in Local Currency – S&P 500 vs. STOXX Europe 600 Since the global financial crisis, the S&P 500 has outperformed its European counterpart by a large margin. Image: Goldman Sachs Global Investment Research
Stoxx Europe 600 and Europe Manufacturing PMI Is the Europe manufacturing PMI rebound in the cards? European stock markets remain bullish. Image: Goldman Sachs Global Investment Research
STOXX Europe 600 EPS Revisions This year, SXXP EPS revisions have not been worse than a typical year. Image: Goldman Sachs Global Investment Research
Europe’s GRANOLAS Stocks and Market Capitalization According to Goldman Sachs, GRANOLAS (Glaxosmithkline, Roche, ASML, Nestle, Novartis, Novo Nordisk, L’Oreal, LVMH, Astrazeneca, SAP and Sanofi) are expected to continue to outperform in the next market cycle, with their collective market cap representing 24% of the Europe’s Stoxx 600 index. Image: Goldman Sachs Global Investment Research